Filing summary
Entity discrepancy: The request identifies CalciMedica, Inc., but the supplied Form 10-Q is for Graybug Vision, Inc. This summary reflects the filing provided, not a CalciMedica filing.
Business context and reporting period
Unaudited results cover the three months ended March 31, 2022; the balance sheet compares March 31, 2022 with December 31, 2021. Graybug was a clinical-stage biopharmaceutical company focused on ocular diseases, with no approved products or product revenue. Its lead candidate was GB-102 for wet age-related macular degeneration (AMD).
Financial results and liquidity
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $6.1 million | $6.4 million |
| General and administrative expense | $4.1 million | $5.0 million |
| Total operating expenses | $10.2 million | $11.5 million |
| Net loss | $10.1 million | $11.4 million |
| Basic and diluted loss per share | $0.48 | $0.54 |
| Cash used in operating activities | $6.5 million | $9.3 million |
As of March 31, cash and cash equivalents were $8.4 million and short-term investments were $46.9 million, totaling $55.3 million in cash, cash equivalents and investments. Total assets were $60.6 million; total liabilities were $4.3 million; accumulated deficit was $179.3 million. No debt balance was reported, and the company stated it had no credit facility or committed sources of capital. With no revenue, profit margins are not meaningful.
Changes versus the prior period
- Net loss improved by $1.3 million year over year; operating expenses fell 11%.
- R&D expense declined 6%, as lower clinical and vendor costs and reduced R&D headcount offset a $2.2 million RainBio in-process research and development charge.
- G&A expense declined 18%, mainly because Q1 2021 included a $1.4 million write-off of fixed-asset purchase deposits.
- Operating cash use improved by $2.7 million. Cash and cash equivalents declined $5.0 million during Q1 2022.
- Unrealized losses on available-for-sale securities were $0.2 million in Q1 2022, compared with a $0.004 million gain in Q1 2021.
Outlook, commentary and risks
- Management estimated that the $55.3 million of cash, cash equivalents and short-term investments would fund operations into Q4 2023, based on its current plan. It also stated funds were adequate for at least 12 months from the report’s issuance. The estimate depends on assumptions and could prove shorter than expected.
- Further Phase 3 development of GB-102 for wet AMD was contingent on obtaining partner funding; without a partnership, further development was uncertain. The company planned an additional open-label Phase 2a trial of an enhanced GB-102 formulation. It expected R&D expense to increase in 2022 and said a GB-401 Phase 1 trial was not expected before the first half of 2023.
- In March 2022, Graybug acquired RainBio’s gene-therapy assets for approximately $2.2 million, expensed as R&D. Additional contingent payments of up to $17.5 million may be due upon specified milestones; none were considered probable or accrued at quarter-end. The acquired program targets corneal clouding associated with MPS1 and had FDA Orphan Drug and Rare Pediatric Disease designations.
- Management cited ongoing losses, the need for additional financing and the possibility that financing may be unavailable or dilutive. Failure to secure funds could require delays, reductions or termination of development programs.
- Clinical risks include GB-102’s prior trial results: the company reported lower average visual-acuity results than the Eylea control in its Phase 2b trial, alongside durability findings. The 2 mg dose was discontinued after anterior-chamber medication and ocular adverse events, including serious events in earlier testing.
- Other stated risks include clinical and regulatory uncertainty, reliance on outside manufacturers and trial providers, competition, intellectual-property exposure, and possible COVID-19 effects on trials or supply. No material litigation was reported. Disclosure controls were assessed as effective.
Important facts for investors to verify
- Confirm the filing identity: the supplied report is Graybug Vision’s, not CalciMedica’s.
- Check subsequent cash use, financing, and whether the stated runway into Q4 2023 was achieved.
- Verify whether Graybug secured a partner for GB-102 and what clinical-development plan followed.
- Review updated GB-102 efficacy and safety data, including visual acuity, durability, and formulation changes.
- Track RainBio milestone terms and any payments or progress in the acquired gene-therapy program.
- Reconcile the reported cash-flow presentation with the $2.2 million acquisition expense and payment, and assess the effect of noncash compensation and investment maturities.